Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | CDC25B | P30305 | 4/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24688350 | 0.81 | HCAR2 (0.38) | HCAR3GPR84HCAR2 | |
| SCHEMBL22692196 | 0.73 | HCAR2 (0.34) | HCAR3GPR84HCAR2 | |
| SCHEMBL22815348 | 0.71 | CYP1A2 (0.39) | HCAR3GPR84HCAR2 | |
| SCHEMBL22815352 | 0.71 | CYP1A2 (0.39) | HCAR3GPR84HCAR2 | |
| SCHEMBL19362661 | 0.71 | CYP1A2 (0.39) | HCAR3GPR84HCAR2 | |
| SCHEMBL18558528 | 0.68 | MAPT (0.32) | GPR84HCAR2MAPT | |
| SCHEMBL21210866 | 0.68 | GPR84 (0.40) | HCAR3GPR84HCAR2ALPLNPC1 | |
| SCHEMBL19362616 | 0.67 | AURKA (0.33) | GPR84HCAR2 | |
| SCHEMBL19362615 | 0.67 | HPGD (0.32) | GPR84HCAR2TP53SMN1; SMN2 | |
| SCHEMBL22502874 | 0.67 | CHEK1 (0.53) | CHEK1RETPDGFRBPIM1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CHEK1 2915/4885RET 4720/4885PDGFRB 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.